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The global scale-up of antiretroviral treatment in past years has, unfortunately, not been accompanied
by adequate strengthening of laboratory capacity. Monitoring of treatment with HIV viral load and
resistance testing, as recommended in industrialized countries, is rarely available in resource-limited
settings due to high costs and stringent requirements for storage and transport of plasma.
Consequently, treatment failure usually passes unnoticed until severe symptoms occur, when resist-
ance mutations have accumulated and second-line drug options are restricted. Dried blood spots
(DBS) are easy to collect and store, and can be a convenient alternative to plasma. Recently, a number
of studies have demonstrated the feasibility and reliability of using DBS to monitor viral load and geno-
typic resistance. Moreover, several African countries have already started to use DBS for paediatric
HIV screening. In the absence of point-of-care assays, the WHO should encourage virological monitor-
ing on DBS in antiretroviral treatment programmes in resource-limited settings.
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The challenge: treating HIV/AIDS where there
is limited laboratory capacity
Immense efforts and resources have been put into the global
scale-up of antiretroviral treatment (ART) in resource-limited
settings in past years. By the end of 2007, 3 million people were
receiving ART in low- and middle-income countries, which is a
.10-fold increase since 2002.1 Price reductions on antiretroviral
drugs from more than US$10000 to less than US$100 per
person per year have been instrumental in the campaign for
universal access to ART.2 Unfortunately, the rollout of treatment
programmes has not been accompanied by a similar strengthening
of laboratory capacity (Figure 1). While prices for antiretroviral
drugs have decreased dramatically due to generic competition, the
costs of laboratory equipment needed to monitor treatment have
remained high.
The honeymoon for global scale-up is over. Early treatment
success has been reported from ART programmes in many low-
income countries, but to uphold the success will demand a sus-
tained effort from donor agencies as well as local ministries of
health. Until now the main focus has been on quantity, such as
the ‘3 by 5’ initiative from the World Health Organization
(WHO), which aimed for 3 million people on ART by 2005,
and more recently the goal of universal access by 2010.
However, as more and more patients are receiving ART
worldwide, the focus must shift from rapid scale-up to
quality-assured scale-up and ensuring long-term success of
therapy.
In high-income countries, monitoring of ART with viral load
and genotypic resistance testing are considered mandatory
elements of patient care, in order to determine when treatment
fails and tailor new regimens in failing patients.3 These tests,
however, are expensive and technically complex, and remain
unavailable to the vast majority of HIV-infected individuals
globally. Thus, clinicians in low-income countries are often left
virtually blindfolded in the assessment of treatment failure, the
need for second-line therapy and HIV status in infants.
Dried blood spots: a long-standing experience
In the absence of low-tech point-of-care assays for virological
monitoring, an alternative strategy could be the shipment of
specimens from peripheral clinics to central laboratories.
However, stringent requirements for storage and transport of
plasma are barriers in settings with a limited infrastructure.
Dried blood spots (DBS) can be an alternative to plasma
samples, and have been used for .40 years to screen for meta-
bolic disorders in neonates.4 DBS specimens are collected by
spotting whole blood onto filter paper (Figure 2), either from
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venous blood or directly from a finger prick, making this
method particularly suitable in rural settings. Furthermore, DBS
packed in zip-lock plastic bags with desiccant can be stored and
shipped at ambient temperature, thus avoiding the need for cold
chain and speedy transport to the laboratory.5 The consumable
costs for DBS are less than US$1 per test, and transport costs
are markedly reduced compared with plasma, although the
actual assay costs remain unchanged, and the extraction of
nucleic acids from DBS involves some extra hands-on time at
the central laboratory.6,7
Viral load quantification using DBS
Viral load measurements are mainly used to monitor the efficacy
of antiretroviral therapy. When viral loads are unavailable, the
WHO recommends that treatment failure should be assessed by
clinical signs or CD4 cell counts.8 However, clinical symptoms
and CD4 decline have poor sensitivity and specificity in detect-
ing virological failure.9 Hence, patients with adequate virologi-
cal suppression risk undergoing a premature switch to costly and
complex second-line therapy. Furthermore, patients with actual
treatment failure risk not being detected until they develop
severe clinical symptoms, and prolonged exposure to a failing
ART regimen leads to accumulation of resistance mutations,
thus jeopardizing future treatment options.
Standard viral load assays are based on nucleic acid amplifi-
cation of HIV-1 RNA. These assays are complex, expensive and
require electricity, air conditioning and clean water, which
usually limit their use to larger hospitals in capital cities or
research projects. Newer assays based on real-time PCR or
nucleic acid sequence-based amplification (NASBA) technology,
although less expensive, have the same limitations. An alterna-
tive enzyme-linked immunosorbent assay (ELISA)-based assay
exists, which measures reverse transcriptase activity (ExaVir
Load; Cavidi AB, Uppsala, Sweden). However, this assay is
time-consuming, involves several steps and the cost is still high.
A dipstick PCR assay is under development by a research group
at Cambridge University,10 but this assay is not yet commer-
cially available.
Several studies from North America and Europe have shown
that DBS can be used to reliably measure viral load.5,11 – 13 More
recently, our own work in rural Tanzania has demonstrated the
feasibility and reliability of using DBS for viral load monitoring
under basic field conditions.14 Indeed, we found that DBS, in
combination with the NucliSENS EasyQ HIV-1 assay
(BioMe´rieux, Inc., Madrid, Spain), had a sensitivity of 91% and
a specificity of 97% in detecting major virological failure,
defined as a plasma viral load of 5000 copies/mL. DBS have
also been evaluated for non-B subtypes showing consistently
satisfactory results.14 – 16
Drug resistance testing using DBS
Genotypic resistance testing is mainly used in patients who
experience treatment failure, in order to tailor a new fully active
regimen.3 With an increasing number of patients receiving ART
for years in resource-limited settings, the need for resistance
testing, at a public health level and at an individual level for
selected cases, can no longer be neglected. Switching blindly to
a new regimen will become virtually impossible when patients
need third- and fourth-line ART. Genotypic resistance testing is
complex and expensive, and requires advanced laboratories with
PCR capacity, limiting its use to major cities. Ideally, a low-tech
point-of-care test should be developed, and an acceptable
alternative could be a simplified assay only for selected signa-
ture mutations.
Recently, several studies have evaluated the use of DBS for
drug resistance testing. In a study on HIV subtype B-infected
individuals from Spain, all 46 DBS specimens from patients
with a viral load of 500 copies/mL were successfully amplified
using the commercial ViroSeq assay (Abbott Molecular,
Des Plains, IL, USA).17 Other studies have found amplification
rates of 90.1%–92.5% in DBS specimens from Mexico and
Cameroon using in-house PCR assays.18,19 A study using the
commercial Trugene HIV-1 Genotyping Kit (Siemens Medical
Solutions Diagnostics, Tarrytown, NY, USA) reported successful
amplification in 78.8% of DBS specimens.20 All these studies
found a high concordance between resistance mutations in
plasma and DBS, and an overall nucleotide similarity ranging
from 98.1% to 99.95%. Our own experiences with the use
of DBS in rural Tanzania support these findings; .90% of
DBS specimens from patients with virological failure were
Figure 1. HIV testing in rural Tanzania with basic laboratory facilities.
Figure 2. DBS on a Whatman 903 filter paper.
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successfully amplified, and there was good agreement with
mutations found in plasma.21
The WHO, in collaboration with a network of international
experts (HIVResNet), recently published a laboratory strategy
for surveillance of HIV drug resistance, where the use of DBS
was recommended in resource-limited settings.22 This method
was successfully employed in surveys of transmitted resistance
in Tanzania and Malawi.23,24 However, until now, the WHO has
only focused on the role of DBS in public health surveillance,
and not in the clinical management of individual patients.
DBS as a tool for HIV screening in neonates
HIV-infected infants represent a particular concern with regard
to diagnosis, treatment and monitoring. A major obstacle to pae-
diatric ART is the difficulty of diagnosing HIV in infants. The
persistence of maternal anti-HIV antibodies until 12–18 months
of age precludes the use of rapid antibody tests, and the cost and
complexity of PCR assays limit their use in resource-limited
settings.25
Recently, several African countries have started to use DBS
in order to expand the accessibility of HIV testing for infants
exposed to vertical HIV transmission.26 Detection of HIV-1
DNA in DBS is a highly sensitive and specific test of HIV infec-
tion in infants,27 and early diagnosis and treatment is key to
reducing mortality in this age group.28 Hence, the use of DBS is
already familiar to healthcare providers and laboratory tech-
nicians in several low-income countries, and this can serve as a
model for further expansion of DBS monitoring strategies in
such settings. Nonetheless, most HIV-exposed infants worldwide
still lack access to a reliable HIV screening test, and without
treatment more than one-third of HIV-infected children will not
survive past their first birthday.25
Limitations of DBS in HIV monitoring
The use of DBS is not without caveats. First, the small
amount of blood in a dried spot gives a reduced sensitivity in
detecting HIV-1 RNA when the viral burden is low (,1000–
4000 copies/mL).5,13,14 On the other hand, in the updated 2006
guidelines, the WHO recommends conservation of first-line
ART in resource-limited settings as long as viral load does not
exceed 10000 copies/mL.8 We believe, therefore, that in the
absence of evidence to support regimen switching at
,1000 copies/mL, DBS are sufficiently sensitive to decide who
needs second-line ART in such settings.
Second, since DBS consist of whole blood instead of plasma,
cell-associated proviral DNA can contribute to the end product.
This can explain why some studies have found false-positive
viral load results in DBS.29,30 However, this problem can be
overcome by using a viral load assay based on NASBA technol-
ogy, like the NucliSENS EasyQ HIV-1 assay (BioMe´rieux,
Inc.), which is an isothermal transcription-based amplification
system designed specifically for RNA detection.31,32 With regard
to resistance testing, it has been shown that proviral DNA may
affect results by contributing historically archived
sequences.33,34 Nevertheless, most studies have found good
agreement between genotypes generated from plasma and
DBS.17 – 21
Third, adequate storage conditions for DBS have yet to be
established. For viral load quantification, some studies suggest a
significant loss of HIV-1 RNA after 1–3 months storage at room
temperature.11,15 In contrast, a multicenter study from North
America found stable HIV-1 RNA levels in DBS stored at room
temperature for at least 1 year.5 With regard to resistance testing,
recent studies showed that genotyping was highly efficient in
DBS stored at 48C for 1 year,35 although storage at extreme con-
ditions (378C and 100% humidity) resulted in a rapid decline in
the efficiency of genotyping after just 2 weeks.36 For clinical
monitoring of patients on ART, monthly shipment of DBS to a
reference laboratory would probably be appropriate, both to
avoid degradation of HIV-1 RNA, and to assure a timely switch
to second-line ART in case of treatment failure.
Steps to action
There is an urgent need for virological monitoring tools devel-
oped specifically to operate under basic field conditions in
resource-limited settings. Ideally, an affordable, simple and
robust point-of-care assay should be developed. Donor agencies,
decision-makers and the laboratory industry have a responsibility
to invest in the development of laboratory equipment for low-
income countries, in order to ensure the long-term success of
ART worldwide.
Unfortunately, field-adapted tools for virological monitoring
are not yet available. In the meantime, a monitoring strategy
based on DBS is the only viable option and should be included
in the next revision of the WHO guidelines, in order to meet the
growing need for viral load, genotypic resistance and infant
diagnosis testing in resource-limited settings. Otherwise the tre-
mendous gains in HIV treatment in past years might be lost in
the coming decade.
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